Ekso Bionics to Showcase Its Device Technology in ‘AI for Good’ Webinar on Tuesday, November 19
SAN RAFAEL, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Katherine Strausser, Principal Controls Engineer at Ekso Bionics, will be participating in an ‘AI for Good’ webinar.
The webinar, entitled “AI-powered Exoskeletons Revolutionizing Rehabilitation and Mobility”, will take place on Tuesday, November 19 at 10:00 a.m. ET. The session will explore the latest exoskeleton technologies and challenges, illustrating how these technologies are not just assisting in overcoming physical limitations but are paving the way for a new era in medical rehabilitation. To register for the webinar, click here.
Katherine holds a Ph.D. in Mechanical Engineering and a master’s degree from the University of California at Berkeley, and a bachelor’s degree from Carnegie Mellon University. As one of the original inventors of the EksoNR device, Katherine primarily focuses on controls systems for robotics and the interaction of humans with exoskeleton devices.
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: www.eksobionics.com or follow @EksoBionics on X.
Contact:
David Carey
212-867-1768
investors@eksobionics.com
Released November 18, 2024